share_log

8-K: Current report

SEC announcement ·  Apr 16 09:35
Summary by Moomoo AI
On April 16, 2024, Incannex Healthcare Inc., a clinical stage pharmaceutical development company, provided a quarterly update for Q1 2024, detailing progress in their research and development programs. The update highlighted the advancement of their therapeutic pipeline, including the IHL-42X drug candidate for Obstructive Sleep Apnea (OSA), which is currently in Phase 2/3 clinical trials. The company also reported on IHL-675A for Rheumatoid Arthritis (RA), which is in Phase 2b studies, and the Psi-GAD psilocybin treatment protocol for generalized anxiety disorder, now entering Phase 2b studies following a successful Phase 2 proof of concept. Additionally, Incannex opened its first Clarion Clinic for psychedelic-assisted psychotherapies. The company is preparing for patient dosing in the RePOSA Phase 2/3 Clinical Trial for IHL-42X and has made significant progress in the...Show More
On April 16, 2024, Incannex Healthcare Inc., a clinical stage pharmaceutical development company, provided a quarterly update for Q1 2024, detailing progress in their research and development programs. The update highlighted the advancement of their therapeutic pipeline, including the IHL-42X drug candidate for Obstructive Sleep Apnea (OSA), which is currently in Phase 2/3 clinical trials. The company also reported on IHL-675A for Rheumatoid Arthritis (RA), which is in Phase 2b studies, and the Psi-GAD psilocybin treatment protocol for generalized anxiety disorder, now entering Phase 2b studies following a successful Phase 2 proof of concept. Additionally, Incannex opened its first Clarion Clinic for psychedelic-assisted psychotherapies. The company is preparing for patient dosing in the RePOSA Phase 2/3 Clinical Trial for IHL-42X and has made significant progress in the Phase 2 clinical trial for IHL-675A. Incannex also intends to submit a New Drug Application for IHL-42X using the FDA 505(b)2 pathway, based on a Bioavailability/Bioequivalence Study. The company's CEO, Joel Latham, expressed confidence in the market potential for their products, citing the lack of FDA or EMA registered drugs for the treatment of sleep apnea. Incannex is listed on NASDAQ as IXHL and holds 19 granted patents with 30 pending applications, focusing on developing treatments for a range of conditions including OSA, traumatic brain injury, lung inflammation, RA, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain.

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more